Memantine Zentiva

Memantine Hydrochloride, the active ingredient in Memantine Zentiva, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients.

GNH USA supplies Memantine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is an NMDA receptor antagonist used in the management of neurodegenerative conditions.

- Alzheimer’s disease (moderate to severe): helps improve cognition, memory, and daily functional abilities in affected adults.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Somnolence

Serious or Rare Side Effects: - Seizures - Hallucinations or psychosis - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Cardiac arrhythmias - Significant liver enzyme elevations

Memantine should be used with consideration of patient‑specific factors and proper storage.

- Renal impairment: dose adjustment may be required. - Hepatic impairment: monitor liver function tests. - History of seizures: use with caution and monitor closely. - Concomitant NMDA antagonists: avoid combined use. - Pregnancy and breastfeeding: safety not established; weigh benefits against risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Amantadine - Dextromethorphan - Ketamine - Quinidine - Other NMDA‑receptor antagonists

Moderate Interactions (Monitor Closely): - Anticholinergic agents - Central nervous system depressants - Antihypertensive drugs - Diuretics - Carbamazepine